关注
Reed F Beall
标题
引用次数
引用次数
年份
Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis
R Beall, R Kuhn
PLoS medicine 9 (1), e1001154, 2012
1892012
Evaluating the impact of the Orphan Drug Act’s seven-year market exclusivity period
A Sarpatwari, RF Beall, A Abdurrob, M He, AS Kesselheim
Health Affairs 37 (5), 732-737, 2018
532018
Is patent “evergreening” restricting access to medicine/device combination products?
RF Beall, JW Nickerson, WA Kaplan, A Attaran
PLoS One 11 (2), e0148939, 2016
502016
Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997
B Sahragardjoonegani, RF Beall, AS Kesselheim, A Hollis
Journal of pharmaceutical policy and practice 14, 1-8, 2021
422021
Pre-market development times for biologic versus small-molecule drugs
RF Beall, TJ Hwang, AS Kesselheim
Nature Biotechnology 37 (7), 708-711, 2019
362019
Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement
RF Beall, R Kuhn, A Attaran
Health Affairs 34 (3), 493-501, 2015
302015
Modes of delivery in preventive intervention studies: a rapid review
RF Beall, N Baskerville, M Golfam, S Saeed, J Little
European journal of clinical investigation 44 (7), 688-696, 2014
302014
A method for approximating future entry of generic drugs
RF Beall, JJ Darrow, AS Kesselheim
Value in Health 21 (12), 1382-1389, 2018
292018
Patent term restoration for top-selling drugs in the United States
RF Beall, JJ Darrow, AS Kesselheim
Drug Discovery Today 24 (1), 20-25, 2019
252019
Tertiary patenting on drug–device combination products in the United States
RF Beall, AS Kesselheim
Nature Biotechnology 36 (2), 142-145, 2018
252018
A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications
SM Baxi, R Beall, J Yang, TK Mackey
Globalization and Health 15, 1-14, 2019
232019
COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022
B Lau, M Tadrous, C Chu, L Hardcastle, RF Beall
Cmaj 194 (23), E801-E806, 2022
192022
The characteristics of patents impacting availability of biosimilars
VL Van de Wiele, RF Beall, AS Kesselheim, A Sarpatwari
Nature Biotechnology 40 (1), 22-25, 2022
182022
Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines
RF Beall, JW Nickerson, A Attaran
Open Medicine 8 (4), e130, 2014
182014
The global intellectual property ecosystem for insulin and its public health implications: an observational study
WA Kaplan, RF Beall
Journal of Pharmaceutical Policy and Practice 10, 1-9, 2017
172017
Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986–2020: Study examines patents and regulatory exclusivities on inhalers for asthma and COPD from 1986 …
WB Feldman, D Bloomfield, RF Beall, AS Kesselheim
Health Affairs 41 (6), 787-796, 2022
152022
Patents and regulatory exclusivities on GLP-1 receptor agonists
R Alhiary, AS Kesselheim, S Gabriele, RF Beall, SS Tu, WB Feldman
JAMA 330 (7), 650-657, 2023
132023
First‐line pharmacotherapy for incident type 2 diabetes: prescription patterns, adherence and associated costs
DJT Campbell, DB Campbell, Y Ogundeji, F Au, R Beall, PE Ronksley, ...
Diabetic Medicine 38 (9), e14622, 2021
132021
The generic drug industry embraces a faster, cheaper pathway for challenging patents
JJ Darrow, RF Beall, AS Kesselheim
Applied Health Economics and Health Policy 17, 47-54, 2019
132019
Insulin Patent Profile
W Kaplan, R Beall
Amsterdam: Health Action International, 2016
132016
系统目前无法执行此操作,请稍后再试。
文章 1–20